Videos

Progress of Ivantis' Hydrus Microstent 2017

Progress of Ivantis’ Hydrus Microstent

By Mario Admin | May 11, 2017

Dave Van Meter, president and CEO of Ivantis, updated OIS@ASCRS attendees on the Hydrus Microstent. Ivantis, like Glaukos, is focused on using the Schlemm’s canal…

Read More
Progress of InnFocus' MicroShunt 2017

Progress of InnFocus’ MicroShunt

By Mario Admin | May 11, 2017

Russ Trenary, president and CEO of InnFocus, updated OIS@ASCRS on the progress of MicroShunt, which the company says could be the first and only surgical…

Read More
Progress of EyeGate Pharma's Ocular Bandage Gel & EPG-54 2017

Progress of EyeGate Pharma’s Ocular Bandage Gel & EPG-54

By Mario Admin | May 11, 2017

Stephen From, CEO of EyeGate Pharma, updated OIS@ASCRS on its acquisition of Jade Therapeutics’ Hyaluronic Acid program. The company paired the HA to create the…

Read More
Progress of ClarVista's Harmoni Modular Intraocular Lens 2017

Progress of ClarVista’s Harmoni Modular Intraocular Lens

By Mario Admin | May 11, 2017

Paul McLean, ClarVista Medical’s CEO, stressed the importance of rotational stability as he extolled the benefits of the company’s Harmoni Modular Intraocular Lens (IOL). The…

Read More
Cassini's Direction for 2017

Cassini’s Direction for 2017

By Mario Admin | May 11, 2017

Mark Packer, MD, chief medical officer at Cassini, told OIS@ASCRS the cornea measurement company is moving into the diagnosis of dry eye disease. The firm…

Read More
Progress of Avedro's Corneal Remodeling Technology 2017

Progress of Avedro’s Corneal Remodeling Technology

By Mario Admin | May 11, 2017

Reza Zadno, president and CEO of Avedro, told OIS@ASCRS attendees that the company’s corneal remodeling technology could reach a huge untapped market of people who…

Read More
Commercial and Strategic Overview of AcuFocus - 2017

Commercial and Strategic Overview of AcuFocus

By Mario Admin | May 11, 2017

Yari Mitchell, VP, Global Medical Affairs & Business Strategy, delivered a commercial overview and laid out some of the changes AcuFocus has made to its…

Read More
Clinical Progress for Rhopressa and Roclatan 2017

Clinical Progress of Aerie Pharmaceuticals’ Rhopressa and Roclatan

By Mario Admin | May 11, 2017

Tom Mitro, chief operating officer of Aerie Pharmaceuticals, brought the OIS@ASCRS community up-to-date on the clinical progress for Rhopressa and Roclatan. The company is entering…

Read More

LensGen Climbs Out of Presbyopia `Penalty Box’

By Mario Admin | May 11, 2017

LensGen CEO Ram Rao, in disussing his $21 million Series A financing, answers a few questions: How did he fund the company until now? What…

Read More

Co-chairs Wrap-up Successful OIS@ASCRS

By Mario Admin | May 7, 2017

Emmett Cunningham, MD, Gil Kliman, MD, and Bill Link, PhD, co-chairs of OIS, talk about device funding, myopia, and the Masters of the Industry following…

Read More
Oculeve Receive OIS Innovator Award

Oculeve Receive OIS Innovator Award

By Mario Admin | May 5, 2017

Conceived just a few years ago by a team of students at the Stanford Biodesign program, Oculeve’s TrueTear device is positioned to provide desperately needed…

Read More

TEClens

By Mario Admin | January 6, 2017

Based in New York, TECLens, LLC is an early-stage medical device company focused on the growing, global epidemic of myopia. The company was founded in…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.